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Abstract 
COVID-19 starts as a respiratory disease that can progress to pneumonia, severe acute 
respiratory syndrome (SARS), and multi-organ failure. Growing evidence suggests that COVID-
19 is a systemic illness that primarily injures the vascular endothelium, yet the underlying 
mechanisms remain unknown. SARS-CoV-2 infection is believed to trigger a cytokine storm that 
plays a critical role in the pathogenesis of endothelialitis and vascular injury, eventually leading 
to respiratory and multi-organ failure in COVID-19 patients. We used a multiplex immunoassay 
to systematically profile and compare 65 inflammatory cytokines/chemokines/growth factors in 
plasma samples from 24 hospitalized (severe/critical) COVID-19 patients, 14 mild/moderate 
cases, and 13 healthy controls (HCs). Patients with severe/critical and mild/moderate COVID-19 
had significantly higher plasma levels of 20 analytes than HCs. Surprisingly, only one cytokine 
(MIF) was among these altered analytes, while the rest were chemokines and growth factors. In 
addition, only MMP-1 and VEGF-A were significantly elevated in hospitalized COVID-19 
patients when compared to mild/moderate cases. Given that excessive MMP-1 plays a central 
role in tissue destruction in a wide variety of vascular diseases and that elevated VEGF-A, an 
EC activation marker, increases vascular permeability, we further studied MMP-1 enzymatic 
activity and other EC activation markers such as soluble forms of CD146, ICAM-1, and VCAM-
1. We found that plasma MMP-1 enzymatic activity and plasma levels of MMP-1 and EC 
activation markers were highly dysregulated in COVID-19 patients. Some dysregulations were 
associated with patients’ age or gender, but not with race. Our results demonstrate that COVID-
19 patients have distinct inflammatory profiles that are distinguished from the cytokine storms in 
other human diseases. Excessive MMP-1 and hyperactivation of ECs occur in COVID-19 
patients and are associated with the severity of COVID-19.  
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Introduction 
Coronavirus disease 2019 (COVID-19), an infectious disease caused by a novel 
coronavirus (severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2), has created an 
unprecedented global health and economic crisis. By the end of 2020, confirmed COVID-19 cases 
surpassed 84 million globally, resulting in over 1.8 million deaths. COVID-19 patients can 
experience a range of manifestations, from being asymptomatic, to having mild, moderate, 
severe symptoms, to having a critical illness. Growing evidence shows that COVID-19 is a 
vascular illness, not solely a respiratory disease. Histopathological examinations of post-mortem 
tissues of COVID-19 patients have revealed (1) diffuse alveolar damage with perivascular 
infiltration of inflammatory cells1-5, (2) extensive damage to the lining of blood vessels 
throughout the body6-8, (3) severe endothelial injury and widespread thrombosis in the lungs, 
heart, liver, kidney, and small intestine1,5-8, (4) viral particles in endothelial cells (ECs) of the 
glomerular capillary loops6, and (5) caspase-3-positive apoptotic ECs in the lung and intestine 
tissues6. In addition, a recent study has shown that COVID-19 patients in intensive care units 
(ICUs) have higher counts of circulating ECs (CECs) than non-ICU patients9. CECs are stressed 
cells detached from injured blood vessels, thereby indicating severe vascular injury10. 
Collectively, patients with severe COVID-19 exhibit impaired endothelial and microcirculatory 
functions across vascular beds of different organs, which may be particularly relevant for 
vulnerable individuals with pre-existing endothelial dysfunctions such as diabetes, obesity, 
hypertension, and cardiovascular diseases, all of which are associated with adverse outcomes 
in COVID-196,11-14. 
The pathological mechanisms underlying vascular injury in COVID-19 remain unclear, 
although cytokine storm syndrome (CSS) and direct SARS-CoV-2 infection are considered 
contributors. SARS-CoV-2 is a member of the family Coronaviridae, genus Betacoronavirus, 
and is closely related to SARS-CoV that caused the 2003 SARS pandemic15-17. CSS plays a 
critical role in the pathogenesis of SARS-CoV infection and represents a major cause of 
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morbidity in SARS patients18,19. Elevated circulating concentrations of IL-6, IFN-γ, IL-8, IL-18, 
TGF-β, IP-10, MCP-1, and MIG have been reported in SARS patients when compared with 
healthy controls (HCs)20,21. Circulating IL-6 levels are also elevated in COVID-19 patients and 
are cited as evidence of COVID-19 CCS22,23. However, the levels of IL-6 and other inflammatory 
cytokines such as IL-8 are significantly less elevated in patients with critical COVID-19 than the 
values typically reported in patients with CSS such as septic shock with and without acute 
respiratory distress syndrome (ARDS)24. Indeed, the concentrations of IL-6, IL-8, and TNF-α, 
three of the most important inflammatory mediators in human diseases with CSS25, in COVID-
19 patients are similar to those found in ICU patients with cardiac arrest or trauma, conditions 
that are not notable for cytokine storms24. These findings bring into question whether a cytokine 
storm occurs in COVID-19, and whether IL-6, IL-8, and TNF-α act as key inflammatory 
mediators for fatal manifestations in patients with severe or critical COVID-1925. Our results 
echo recent NIH guidelines that note there are insufficient data to recommend IL-6 inhibitors for 
the treatment of COVID-1926. In fact, efforts to combat cytokine storm in patients with severe 
COVID-19 have proven unsuccessful27.  
SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as a primary receptor for viral 
binding and entry28-32. Viral entry is also facilitated by transmembrane protease serine 2 
(TMPRSS2) and neuropilin-1 (NRP1)31,33,34. ACE2, TMPRSS2, and NRP1 are highly abundant 
on the lung alveolar type II epithelial (AT2) cells, rendering AT2 cells highly susceptible to 
productive SARS-CoV-2 infection33,35-37. ACE2, TMPRSS2, and NRP1 are also expressed on 
the surface of ECs33,35,38-40, albeit at lower levels than in AT2 cells33, suggesting that these 
molecules may facilitate direct SARS-CoV-2 infection of ECs. Indeed, SARS-CoV-2 particles 
were observed in ECs in kidney tissues from COVID-19 patients8. However, a recent 
unreferenced preprint reported that ECs derived from human peripheral blood mononuclear 
cells (PBMCs), human lung microvascular ECs, and human aortic ECs did not have detectable 
mRNA of ACE2 and TMPRSS2 and were resistant to SARS-CoV-2 infection in vitro41. Although 
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this study shows results that are not consistent with both their own report42 and previous 
studies33,35,38-40, it highlights the need for further research on the pathogenic mechanisms 
underlying vascular injury in COVID-19. 
To explore the profile and key players of the cytokine storm in COVID-19, we used a 
multiplex immunoassay to simultaneously measure 65 inflammatory 
cytokines/chemokines/growth factors in plasma samples from hospitalized (severe/critical) 
COVID-19 patients, mild/moderate cases, and HCs. Surprisingly, matrix metalloproteinase-1 
(MMP-1) and vascular endothelial growth factor A (VEGF-A), not conventional inflammatory 
cytokines such as IL-6, were two of the most unambiguously elevated inflammatory factors in 
hospitalized COVID-19 patients when compared to mild/moderate cases or HCs. Spearman 
correlation analysis revealed that the plasma levels of MMP-1 and VEGF-A in hospitalized 
COVID-19 patients were positively correlated, suggesting that there may be an interaction 
between MMP-1 and VEGF-A in COVID-19. Given that excessive MMP-1 plays a central role in 
tissue destruction in a wide variety of vascular diseases and that elevated VEGF-A, an EC 
activation markers, increases vascular permeability43, we further studied MMP-1 enzymatic 
activity and other EC activation markers including soluble forms of CD146, intercellular 
adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1) in our cohort 
of COVID-19 patients and HCs. We performed correlation analysis among plasma levels of 
MMP-1, EC activation markers, and inflammatory cytokines/chemokines, MMP-1 enzymatic 
activity, and patients’ demographics and clinical parameters. We found that excessive MMP-1 
and hyperactivation of ECs occurred in COVID-19 patients and were correlated with the severity 
of COVID-19. 
 
Materials and methods 
 
Study subjects and ethical considerations 
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        This study was performed with the approval of the Institutional Review Boards at Indiana 
University School of Medicine. Blood samples were drawn after each participant provided a 
written informed consent form.  
Combined nasopharyngeal-oropharyngeal swab specimens collected from study subjects 
were tested using either the cobas® SARS-CoV-2 Test (Roche Diagnostics, Indianapolis, IN) 
real-time PCR assay performed on either the cobas® 6800 or 8800 platforms or the NxTAG® 
CoV Extended Panel (Luminex Molecular Diagnostics, Toronto, ON, Canada) reverse-
transcription PCR assay. Diagnostic tests were used in accordance with manufacturer 
instructions for use pursuant to U.S. Food and Drug Administration Emergency Use 
Authorization. 
The study subjects included 24 hospitalized COVID-19 patients, 14 mild/moderate cases, 
and 13 HCs. Hospitalized COVID-19 patients included SARS-CoV-2-infected individuals who 
developed severe illness (dyspnea, hypoxia, >50% lung involvement on imaging, or required 
oxygen support44) or critical disease with complications such as respiratory failure, disseminated 
intravascular coagulation (DIC), and/or multi-organ failure44. Some of these hospitalized patients 
were admitted to ICUs. Patients with mild/moderate COVID-19 were characterized with mild 
respiratory symptoms (nasal congestion, runny nose, and a sore throat) or mild pneumonia44. All 
COVID-19 patients were treated in Indiana University (IU) Health hospitals in Indianapolis, 
Indiana, during May – December 2020. Plasma samples from HCs were selected from our 
banked blood samples that were collected before the COVID-19 pandemic as described in our 
previous reports45,46. Demographics of HCs were matched with COVID-19 patients so that there 
were no significant differences between age or gender of HCs and COVID-19 subjects. The 
demographic and clinical characteristics of COVID-19 patients and HC demographics were 
summarized in Table 1. 
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Multiplex and ELISA immunoassays 
Peripheral blood was collected in heparin-coated BD Vacutainer Blood Collection tubes 
(BD Biosciences, Franklin Lakes, NJ). Blood samples were centrifuged within 12 h of collection 
at 700 g for 20 min at room temperature without brake. The top layer (plasma) was harvested 
and stored at -80 ºC until use. Plasma concentrations of 65 human 
cytokines/chemokines/growth factors including 33 cytokines (G-CSF, GM-CSF, IFN-α, IFN-γ, IL-
1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-16, IL-17A, 
IL-18, IL-20, IL-21, IL-22, IL-23, IL-27, IL-31, LIF, M-CSF, MIF, TNF-α, TNF-β, and TSLP), 18 
chemokines (CXCL13, CXCL5, CCL11, CCL24, CCL26, CX3CL1, CXCL1, CXCL10, CXCL11, 
MCP-1, MCP-2, MCP-3, MDC, MIG, MIP-1α, MIP-1β, MIP-3α, and SDF-1α), 6 growth 
factors/regulators (FGF-2, HGF, MMP-1, NGF-β, SCF, VEGF-A), and 8 soluble receptors 
(APRIL, BAFF, CD30, CD40L, IL-2R, TNF-RII, TRAIL, and TWEAK) were simultaneously 
measured using a magnetic bead-based multiplex kit (65-Plex Human ProcartaPlexTM Panel, 
EPX650-10065-901, Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. 
Briefly, plasma samples were incubated with beads at room temperature for 2 h with shaking at 
500 rpm, and subsequently washed twice using a magnetic plate washer (eBioscience, San 
Diego, CA). The beads were incubated with the biotinylated antibodies for 1 h at room 
temperature with shaking at 500 rpm. After washing, beads were incubated with streptavidin-PE 
for 30 min at room temperature with shaking at 500 rpm. After washing twice, beads were 
resuspended in PBS and read on a BioPlex 200 system (Bio-Rad, Hercules, CA) with a setting 
of 40 beads per bead set and 150 seconds per well. The standards at four-fold serial dilutions 
were run on each plate in duplicate and used to calculate the concentrations of 
cytokines/chemokines/growth factors using the Bio-Plex Manager Software (Bio-Rad, Hercules, 
CA). 
Plasma levels of soluble CD146 (sCD146), soluble ICAM-1 (sICAM-1), soluble VCAM-1 
(sVACM-1), and intestinal fatty-acid binding protein (I-FABP) were quantified using the Human 
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CD146 DuoSet ELISA Kit, the Human ICAM-1 DuoSet ELISA Kit, the Human VCAM-1 DuoSet 
ELISA Kit, and the Human I-FABP DuoSet ELISA kit (all from R&D Systems, Minneapolis, MN), 
respectively, according to manufacturer’s instructions. ELISA results were recorded using a 
microplate reader system (Bio-Tek, Winooski, VT). 
 
Quantitative determination of human active MMP-1 in plasma samples. 
Enzymatic activity of plasma MMP-1 was determined using the Human Active MMP-1 
Fluorokine E kit (F1M00, R&D Systems, Minneapolis, MN) as per manufacturer’s instructions. 
Briefly, diluted plasma samples and MMP-1 standards were added to the wells that were pre-
coated with a monoclonal antibody specific for human MMP-1. After washing to remove 
unbound substances, amino-phenyl mercuric acetate (APMA), an activation reagent of MMP-1, 
was added to the standards, but not the plasma samples. After washing, a fluorogenic substrate 
linked to a quencher molecule was added and any active enzyme present would cleave the 
peptide linker between the fluorophore and the quencher molecule, generating a fluorescent 
signal that is proportional to the amount of enzyme activity in an individual sample. Thus, 
plasma levels of active MMP-1 were quantitatively detected using a Synergy H1 Hybrid Multi-
Mode Reader (BioTek, Winooski, VT), where fluorescence emission was recorded in relative 
fluorescence unit (RFU).  
 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6.0 (La Jolla, CA). Data were 
expressed as mean ± standard error of the mean (SEM) or mean ± standard deviation (SD) 
unless otherwise indicated. All data were tested for suitability for parametric or non-parametric 
analysis. Differences between two groups were calculated using the Mann Whitney test. 
Kruskal-Wallis test with Dunn’s corrections was used for comparisons among three groups. Chi-
square test was used for comparison between groups for categorical variables. The linear 
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relationship between two variables was analyzed using the Spearman correlation test. P <0.05 
was considered statistically significant. 
 
Results 
Characteristics of study subjects 
The study subjects included 24 hospitalized patients with severe/critical COVID-19, 14 
patients with mild/moderate COVID-19, and 13 HCs. Severe/critical COVID-19 patients were 
hospitalized in Indiana University (IU) Health hospitals in Indianapolis, Indiana and 
mild/moderate COVID-19 patients visited IU Health hospitals between May – December 2020. 
HCs were recruited before the COVID-19 pandemic for our research on immunopathogenesis of 
HIV infection and alcoholic hepatitis as described in our previous reports45-48. The demographics 
and clinical characteristics of these subjects were summarized in Table 1. There were no 
differences in age, gender, and race distributions among these three groups. Hospitalized 
COVID-19 patients had lower absolute lymphocyte count (ALC), higher erythrocyte 
sedimentation rate (ESR), and higher levels of D-dimer, C-reactive protein (CRP), and ferritin 
than patients with mild/moderate COVID-19 (Table 1). There were no differences in white blood 
cell (WBC) or neutrophil counts between the hospitalized patients and patients with 
mild/moderate COVID (Table 1). 
 
Profiles of inflammatory cytokines/chemokines/growth factors in hospitalized COVID-19 
patients, mild/moderate cases, and HCs 
COVID-19 patients present varied clinical features, ranging from asymptomatic, 
mild/moderate, severe, to critical illness. The pathogenesis of severe or critical COVID-19 is 
complex and has been suggested to include a cytokine storm that sustains an aberrant systemic 
immune response49. To elucidate the profile and key pathogenic inflammatory mediators of the 
cytokine storm in COVID-19 patients, we used a multiplex immunoassay to simultaneously 
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detect plasma levels of 65 cytokines/chemokines/growth factors in hospitalized (severe/critical) 
patients, mild/moderate cases, and HCs. In comparison to HCs, hospitalized and mild/moderate 
COVID-19 patients had significantly higher plasma levels of 20 of these analytes (Table 2). 
Among these altered analytes, macrophage migration inhibitory factor (MIF) was the only 
inflammatory cytokine, all others were chemokines (BLC/CXCL13, ENA-78/CXCL5, Eotaxin-
3/CCL26, Fractalkine/CX3CL1, IP-10/CXCL10, I-TAC/CXCL11, MIG/CXCL9, MIP-1α/CCL3, 
MIP-1β/CCL4, and SDF-1α/CXCL12), growth factors (HGF, MMP-1, SCF, and VEGF-A), and 
soluble receptors (APRIL, CD30, IL-2R/CD25, TNF-RII, and TRAIL/CD253) (Table 2). 
Surprisingly, MMP-1 and VEGF-A were the only two elevated inflammatory factors that were 
significantly higher in hospitalized COVID-19 patients when compared to mild/moderate cases 
(Table 2 and Figure 1A), while all others did not show differences between hospitalized and 
mild/moderate COVID-19 patients (Table 2). Spearman correlation analysis revealed that the 
plasma levels of MMP-1 and VEGF-A in hospitalized COVID-19 patients were positively 
correlated (Figure 1B), indicating that there are interactions between MMP-1 and VEGF-A in 
COVID-19. Thus, the highly elevated plasma levels of MMP-1 and VEGF-A were associated 
with the severity of COVID-19. 
MCP-1, MCP-2, IL-6, and IL-18 were the 4 analytes that were significantly increased in 
hospitalized patients, but not in mild/moderate cases, when compared to HCs (Table 2 and 
Figure 1A). However, plasma levels of IL-6 and IL-18 were elevated in some, but not all, 
patients with severe/critical COVID-19. As shown in Figure 1A, IL-6 was detected in 0 HCs (limit 
of detection ≥7.98 pg/mL), 1 mild/moderate case (67.8 pg/mL), and 7 hospitalized cases (13.8 
pg/mL, 32.7 pg/mL, 68.9 pg/mL, 120.7 pg/mL, 138.2 pg/mL, 169.6 pg/mL, and 325.4 pg/mL). 
Similarly, IL-18 was detected in 0 HCs (limit of detection ≥9.72 pg/mL), 4 mild/moderate cases 
(15.3 – 54.4 pg/mL), and 18 hospitalized patients (15.7 – 127.3 pg/mL). Obviously, the levels of 
IL-6 and IL-8 are significantly less elevated in patients with critical COVID-19 than the values 
typically reported in patients with CSS such as septic shock with and without ARDS24. 
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Nineteen analytes were detected in all three groups of research subjects, but there were 
no differences between these groups (Table 2). Twenty-two analytes, primarily inflammatory 
cytokines such as IL-8 and TNF-α, were below the limit of detection in the majority of 
hospitalized cases, mild/moderate cases, and HCs (Table 2).  
Our data support previous findings that suggested IL-6, IL-8, and TNF-α did not act as key 
inflammatory mediators for fatal manifestations in patients with severe or critical COVID-1925, 
and also question whether cytokine storm occurs in COVID-19. 
 
Enzymatic activity of MMP-1 and activation markers of ECs increased in the peripheral 
blood in hospitalized COVID-19 patients. 
MMP-1 and VEGF-A were two of the most unambiguously elevated inflammatory factors in 
hospitalized COVID-19 patients. Their plasma levels were positively correlated (Table 1 and 
Figure 1), suggesting that there are interactions between MMPs and ECs in COVID-19. To this 
end, we studied plasma MMP-1 enzymatic activity and the EC activation marker profiles. To 
date, only one MMP, MMP-9, has been analyzed in one pilot COVID-19 study50. This study 
measured plasma MMP-9 levels using an enzyme immunoassay, and showed that hospitalized 
COVID-19 patients had higher MMP-9 levels than HCs50. However, none of the MMPs have 
been studied for their enzymatic activity in COVID-19 patients. We analyzed enzymatic activity 
of MMP-1 in plasma samples from HCs and patients with mild/moderate or hospitalized COVID-
19. We found that the enzymatic activity of MMP-1 was significantly increased in hospitalized 
COVID-19 patients when compared to HCs and those with mild/moderate COVID-19 (Figure 
2A). Thus, both the levels and the enzymatic activity of MMP-1 were up-regulated in the 
peripheral blood of COVID-19 patients, particularly in patients with severe/critical COVID-19. 
Next, we used ELISA assays to measure the levels of sCD146, sVCAM-1, and sICAM-1, 
surrogate markers of EC activation, in the plasma samples from hospitalized COVID-19 
patients, mild/moderate cases, and HCs. As shown in Figure 2B, hospitalized COVID-19 
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patients had significantly higher plasma levels of sCD146, sICAM-1, and sVCAM-1, than HCs. 
Mild/moderate COVID-19 patients also had higher levels of sCD146, but neither sICAM-1 nor 
sVCAM-1, than HCs (Figure 2B). There were no differences in the plasma levels of sCD146, 
sICAM-1, or sVCAM-1 between hospitalized and mild/moderate COVID-19 patients (Figure 2B). 
As I-FABP is solely expressed in epithelial cells of the mucosal layer of the small intestine tissue 
and used as a plasma marker of intestinal epithelial injury51,52, I-FABP ELISA assay was also 
performed to study and compare the effects of COVID-19 on epithelial cells versus ECs. In 
contrast to EC activation markers, plasma I-FABP levels were no different among hospitalized 
COVID-19 patients, mild/moderate cases, and HCs (Figure 2C), suggesting that systemic ECs, 
not small intestine epithelial cells, are significantly affected by COVID-19. 
Spearman correlation analysis was performed to identify any associations between 
plasma levels of active MMP-1 and EC activation markers. There was a positive correlation 
between plasma active MMP-1 and plasma levels of sCD146 (r = 0.51 and p<0.039) (Figure 
2D). There were no correlations between the plasma levels of active MMP-1 and plasma levels 
of sICAM-1 or sVCAM-1 in hospitalized COVID-19 patients (data not shown). 
Taken together, our data demonstrate that both plasma level and enzymatic activity of 
MMP-1 and plasma levels of EC activation markers are highly elevated and positively correlated 
in COVID-19 and their dysregulations are associated with the severity of COVID-19. 
 
Association of elevated MMP-1 and EC activation markers with demographics in 
hospitalized COVID-19 patients 
Age is a well-known factor that influences the severity and fatality of COVID-1953. The risk 
for severe illness with COVID-19 increases with age, with older adults at higher risk53. Other 
demographic factors such as sex and race have been also linked with risk for severity of 
COVID-19 illness. We analyzed the relationship between demographic factors and circulating 
MMP-1 and EC activation markers in hospitalized COVID-19 patients. Twenty-four hospitalized 
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COVID-19 patients were split into 2 age groups: 10 cases ≤ 55 years old and 14 cases > 55 
years old. As shown in Figure 3A, plasma VEGF-A levels were significantly higher in 
hospitalized COVID-19 patients >55 years old when compared to cases ≤ 50 years old. Plasma 
levels of MMP-1, sICAM-1, sVCAM-1, active MMP-1 showed an increased trend in the older 
group (Figure 3A).   
We also analyzed the associations of sex and race with MMP-1 and EC activation 
markers. As shown in Figure 3B and 3C, plasma sVCAM-1 levels were significantly higher in 
males (n=10) when compared to females (n=14) (Figure 3B). There were no differences in the 
plasma levels of MMP-1, active MMP-1, and EC activation markers in African-Americans (n=10) 
when compared to Caucasian Americans (n=13) (Figure 3C).   
 
Discussion 
In the present study, we systematically profiled and compared 65 inflammatory 
cytokines/chemokines/growth factors in the plasma samples from hospitalized (severe/critical) 
COVID-19 patients, mild/moderate COVID-19 cases, and HCs. As shown in Table 2, 
hospitalized and mild/moderate COVID-19 patients had significantly higher plasma levels of 20 
out of 65 factors analyzed when compared to HCs. These altered 20 factors include 10 
chemokines (BLC/CXCL13, ENA-78/CXCL5, Eotaxin-3/CCL26, Fractalkine/CX3CL1, IP-
10/CXCL10, I-TAC/CXCL11, MIG/CXCL9, MIP-1α/CCL3, MIP-1β/CCL4, and SDF-1α/CXCL12), 
4 growth factors (HGF, MMP-1, SCF, and VEGF-A), 5 soluble receptors (APRIL, CD30, IL-
2R/CD25, TNF-RII, and TRAIL/CD253), and 1 cytokine (MIF). In addition, four factors, MCP-1, 
MCP-2, IL-6, and IL-18, were significantly increased in hospitalized patients, but not in 
mild/moderate cases, when compared to HCs (Table 2, Figure 1). However, IL-6 and IL-18 were 
only elevated in some patients with severe/critical COVID-19, and their levels were significantly 
less elevated when compared to the values typically reported in patients with CSS such as 
septic shock with and without ARDS24. Thus, the vast majority of altered circulating 
All rights reserved. No reuse allowed without permission. 
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 
The copyright holder for this preprintthis version posted January 20, 2021. ; https://doi.org/10.1101/2021.01.19.21250115doi: medRxiv preprint 
inflammatory factors in COVID-19 patients were chemokines, growth factors, and soluble 
receptors, not inflammatory cytokines. Our results indicate that COVID-19 patients have distinct 
inflammatory profiles that are distinguished from the cytokine storms found in other human 
diseases49,54,55, and also question whether a cytokine storm occurs in COVID-19. The term 
“cytokine storm” was first coined to describe the excessive release of inflammatory cytokines by 
immune cells in graft-versus-host disease (GVHD)49,54,55. Since then, CSS has been reported in 
a wide range of other human diseases including cancer patients undergoing chimeric antigen 
receptor (CAR) T cell therapy56,57, pancreatitis58, multiple organ dysfunction syndrome59, multiple 
sclerosis60, sepsis61, and viral infections21,62-68. Indeed, CSS is a common complication of viral 
respiratory infections such as infection with influenza62,63, SARS-CoV21,64,65, and the Middle East 
respiratory syndrome coronavirus (MERS-CoV)67,68. In these CSS-linked diseases, several 
inflammatory cytokines including IL-6, IFN-γ, IL-1β, and TNF-α are highly elevated. In fact, 
elevated circulating levels of IL-6 are a hallmark of CSS in patients undergoing CAR T cell 
therapy69. In HCs, mean levels of circulating IL-6 have been reported to be <5 pg/mL70, which 
can be increased to >10,000 pg/mL in cancer patients on CAR T cell therapy69. The substantial 
elevation of IL-6 and its correlation with disease severity have resulted in IL-6 inhibitors such as 
sarilumab, siltuximab, and tocilizumab becoming therapeutic agents that can effectively treat 
CSS-associated diseases69,71. Circulating IL-6 levels are also elevated in COVID-19 patients 
and is cited as evidence of COVID-19 CCS22,23,66,72-78. However, as previously reported, 
elevated IL-6 levels in COVID-19 patients are minuscule compared to those found in individuals 
on CAR T cell therapy and other CSS-associated diseases25, suggesting that IL-6 does not act 
as a key inflammatory mediator for fatal manifestations in patients with severe or critical COVID-
1925. In line with this finding, IL-6 inhibitors are not recommended to be used as therapeutic 
agents for the treatment of COVID-19 as noted by NIH guidelines26. Our results provide 
evidence that explains why efforts to combat cytokine storm have proven unsuccessful in 
severe COVID-19 patients. Our study implicates a chemokine storm, not a cytokine storm, 
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occurs in COVID-19. This chemokine storm plays an important role in the pathogenesis of 
COVID-19 via recruitment of inflammatory cells to the lungs and other organs or tissues1-5. 
Thus, chemokines and chemokine receptors as therapeutic targets for COVID-19 treatment 
need to be studied.  
As shown in Table 2 and Figure 1, MMP-1 and VEGF-A were two of the most 
unambiguously elevated inflammatory factors in hospitalized COVID-19 patients when 
compared to mild/moderate cases or HCs, while all other inflammatory factors did not show 
differences between hospitalized and mild/moderate COVID-19 patients. Spearman correlation 
analysis revealed that the plasma levels of MMP-1 and VEGF-A in hospitalized COVID-19 
patients were positively correlated (Figure 1B), suggesting interactions between MMP-1 and 
VEGF-A in COVID-19. MMP-1 is an interstitial collagenase capable of degrading collagen types 
I, II, and III, and plays a critical role in vascular remodeling and vascular diseases79,80. In 
addition, MMP-1 acts as a potent agonist for protease-activated receptor-1 (PAR1)81, a G 
protein-coupled protease-activated receptor, on the surface of a variety of cell types such as 
ECs81-83, platelets81,84,85, and macrophages86,87. MMP-1/PAR1 signaling plays a paramount role 
in EC function81-83. Hyperactivation of MMP-1/PAR1 signaling in ECs leads to a decreased 
endothelial barrier function and promotes adhesion of inflammatory cells to ECs88-90. MMP-
1/PAR1 signaling can increase expression of VEGF receptor-2 (VEGFR2)91, the main receptor 
for VEGF-A92, on ECs. The increased VEGFR2 binds VEGF-A, resulting in increased activation 
of ECs. We found that the levels of MMP-1, VEGF-A, and MMP-1 enzymatic activity were 
significantly elevated in the peripheral blood in hospitalized (severe/critical) COVID-19 patients 
compared to mild/moderate cases or HCs (Figure 2), suggesting that MMP-
1/PAR1/VEGFR2/VEGF-A signaling may be in a hyperactivation state in ECs in COVID-19 
patients.  
In addition to VEGF-A, other EC activation markers including sCD146, sICAM-1, and 
sVACM-1 were highly elevated in COVID-19. In contrast, plasma I-FABP levels were no 
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different between COVID-19 patients and HCs (Figure 2C). These findings indicate that 
systemic ECs, not small intestine epithelial cells, are significantly affected in COVID-19. Taken 
together, our results imply that excessive MMPs are strongly related to the severity of COVID-
19, likely playing a central role in widespread damage to the vascular endothelium. In humans, 
there are 23 related, but distinct, MMPs. Thus, there is an urgent need to study the profile, 
expression, and activity of MMPs in SARS-CoV-2 infection and the role of excessive MMPs in 
the pulmonary and systemic endothelialitis and vascular injury in COVID-19 patients. A better 
understanding of MMP profiles and their pathological roles will provide insights into application 
of therapeutic MMP inhibitors for COVID-19 treatment. 
Age is a well-known factor that influences the severity and fatality of COVID-1953. The risk 
for severe illness with COVID-19 increases with age, with older adults at highest risk53. Other 
demographic factors such as gender and race have been also linked with risk for the severity of 
COVID-19 illness. We found that excessive MMPs and/or circulating markers of EC activation 
increased with age or were higher in hospitalized male COVID-19 patients (Figure 3), but not 
affected by race (Figure 3). However, we realize that our sample size of hospitalized COVID-19 
patients, after splitting into 2 demographic groups, is too small to make statistical inferences.  
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Figure legends 
 
Figure 1. Plasma levels of inflammatory factors highly elevated in hospitalized COVID-19 
patients. A) Scatter plots demonstrating the plasma levels of MMP-1, VEGF-A, MCP-1, MCP-2, 
IL-6, and IL-18 in hospitalized COVID-19 patients (n=24), mild/moderate COVID-19 patients 
(n=14), and HCs (n=13). Kruskal-Wallis test with Dunn’s correction for pairwise comparisons 
among hospitalized COVID-19 patients, mild/moderate COVID-9 patients, and HCs. B) 
Spearman correlation analysis between plasma levels of MMP-1 and VEGF-A in hospitalized 
COVID-19 patients. r, Spearman correlation coefficient. HC, healthy control; Mild, mild/moderate 
COVID-19 patients; Hosp, hospitalized COVID-19 patients. *p < 0.05; **p < 0.01; ***p < 0.001; 
ns, not significant; Horizontal lines represent the median. 
 
Figure 2. Enzymatic activity of MMP-1 and activation markers of ECs were elevated in the 
peripheral blood in hospitalized COVID-19 patients. A), B), and C) Scatter plots 
demonstrating enzymatic activity of MMP-1, levels of EC activation markers (sCD146, sICAM-1, 
and sVCAM-1), and level of intestinal epithelial injury marker (I-FABP), respectively, in the 
peripheral blood from hospitalized COVID-19 patients (n=24), mild/moderate COVID-19 patients 
(n=14), and HCs (n=13). Kruskal-Wallis test with Dunn’s correction for pairwise comparisons 
among HC, hospitalized COVID-19 patients, and mild/moderate COVID-9 patients. B) 
Spearman correlation analysis between plasma levels of MMP-1 and sCD146 in hospitalized 
COVID-19 patients. r, Spearman correlation coefficient. HC, healthy control; Mild, 
mild/moderate COVID-19 patients; Hosp, hospitalized COVID-19 patients. *p < 0.05; **p < 0.01; 
ns, not significant; Horizontal lines represent the median. 
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Figure 3. Relationship of MMP-1 and EC activation with demographics of hospitalized 
COVID-19 patients. Scatter plots demonstrating level of MMP-1, levels of EC activation 
markers (VEGF-A, sCD146, sICAM-1, and sVCAM-1), and level of intestinal epithelial injury 
marker (I-FABP), and enzymatic activity of MMP-1 in hospitalized COVID-19 patients. 
Comparison of these factors between hospitalized COVID-19 patients >55 years old (n=14) and 
≤ 55 years old (n=10) (A), female (n=14) and male (n=10) (B), and African-Americans (n=10) 
and while Americans (n=13) (C), respectively. All comparisons were conducted using Mann 
Whitney test. HC, healthy control; Mild, mild/moderate COVID-19 patients; Hosp, hospitalized 
COVID-19 patients; Black, African-American; White, Caucasian-American. *p < 0.05; ns, not 
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Tables 
Table 1. Demographics and clinical characteristics of COVID-19 patients vs HCs 
  HC (n=13) Mild (n=14) Hosp (n=24) 
Age (years) 56.6 (42.1 - 65.5) 59.0 (43.0 - 63.0) 64.0 (48.5 -73.0) 
Gender (male) 6 (46.3%) 6 (42.9%) 10 (41.7%) 
Race    
      African American 5 (38.5%) 7 (50.0%) 10 (41.7%) 
      White 7 (53.8%) 6 (42.9%) 13 (54.2%) 
      Other 1 (7.7%) 1 (7.1%) 1 (4.1%) 
D-Dimer (ng/mL) <250  282 (259 - 290) 527 (244 - 814)*** 
CRP (mg/L) <10 126 (89 - 268)* 830 (642 - 1,273)*** 
Ferritin (ng/mL) <300 350 (145 - 939) 311 (88 - 1,078) 
WBC (cell number/μL) 4,000-11,000 5,450 (4,200 - 8,100) 8,000 (5,800 - 12,150) 
Neutrophil (ANC/μL) 1,500 - 8,000 3,600 (2,550 - 4,800) 6,300 (4,400 - 10,300) 
Lymphocyte (ALC/μL) 1,000-4,800 1,100 (650 - 1,850) 610 (522 - 660)# 
 
Note: Values of D-Dimer, CRP, ferritin, WBC, ANC, and ALC in HCs are the reference numbers 
for healthy population. *p<0.05, ***p<0.001 (increased), & #p<0.05 (decreased): comparison 
between mild/moderate or hospitalized COVID-19 and HCs. WBC, white blood cell count; ANC, 
absolute neutrophil count; ALC, absolute lymphocyte count; CRP, c-reactive protein; HC, 
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Table 2. Plasma levels of cytokines/chemokines/growth factors in COVID-19 and HC 
Analyte HC (n=13) Mild (n=14) Hosp (n=24) 
BLC (CXCL13)  36 (17 - 73) 92 (45 - 183)* 107 (75 - 185)*** 
ENA-78 (CXCL5) 22.8 (4.6 - 32.4) 94.5 (68.0 - 69.0)*** 108.1 (66.6 - 178.2)*** 
Eotaxin-3 (CCL26) 2.2 (2.2 - 2.2) 6.0 (2.2 - 20.7)** 9.6 (6.3 -18.9)*** 
Fractalkin (CX3CL1) 2.5 (1.7 - 2.5) 3.9 (2.8 - 5.2)* 3.6 (2.7 - 5.6)*** 
IP-10 (CXCL10) 6.4 (3.1 - 9.7) 29.1 (9.2 - 69.9)** 28.8 (16.7 - 87.4)*** 
I-TAC (CXCL11) 11.1 (11.1 - 35.8) 165.6 (92.6 (287.1)**  196.8 (114.2 - 491.2)*** 
MIG (CXCL9) 8.6 (8.6 - 10.3) 37.8 (27.4 - 69.1)*** 26.2 (12.7 - 53.2)** 
MIP-1α (CCL3) 5.3 (3.1 - 26.3) 10.0 (3.1 - 19.2)*** 9.4 (3.5 - 19.4)*** 
MIP-1β (CCL4) 4.6 (4.6 - 4.6) 20.0 (10.0 - 45.8)*** 19.6 (8.8 - 32.7)*** 
SDF-1α (CXCL12) 679 (472 - 989) 1099 (815 - 1274)* 1087 (718 - 1275)** 
HGF 11.9 (6.4 - 17.9) 54.8 (28.4 - 141.1)* 163.2 (77.1 - 357.3)*** 
MMP-1 73.8 (30.9 - 96.1) 316.8 (189.0 - 589.5)** 863.4 (551.4 - 1880)***,# 
SCF 4.6 (3.4 - 8.6) 15.4 (12.4 - 43.6)** 16.6 (8.3 - 26.2)** 
VEGF-A 6.8 (6.8 - 8.2) 124.5 (86.0 - 293.0)*** 353.9 (235.1 - 701.7)****,# 
APRIL 745 (602 - 913) 1951 (1236 - 4852)*** 1883 (1239 - 2515)*** 
CD30 100 (38 - 126) 409 (194 - 936)*** 274 (178 - 703)*** 
IL-2R (CD25) 84 (84 - 1414) 6474 (2006 - 9316)** 6884 (4217 - 9539)*** 
TNF-RII 78.6 (59.1 - 96.4) 221.2 (158.7 - 262.3)*** 202.2 (150.2 - 256.1)*** 
TRAIL (CD253) 11.0 (11.0 - 29.5) 63.3 (41.9 - 103.3)** 41.4 (24.5 - 415.2)* 
MIF 37.7 (19.7 - 48.4) 90.7 (80.3 - 125.1)*** 89.5 (70.7 - 157.2)*** 
MCP-1 (CCL2) 41.1 (21.8 - 59.5) 109.4 (40.1 - 281.5) 172.2 (84.2 - 363.4)** 
MCP-2 (CCL8) 2.8 (0.8 - 4.9) 4.4 (3.1 - 6.2) 5.0 (2.6 - 8.6)* 
IL-6 7.9 (7.9 - 7.9) 7.9 (7.9 - 7.9) 41.9 (7.9 - 76.1)* 
IL-18 9.7 (4.2 - 9.7) 9.7 (9.1 - 20.5) 21.8 (9.7 - 56.5)*** 
CD40L (CD154) 4.8 (4.8 - 82.0) 29.5 (17.6 - 71.2) 36.6 (19.7 - 59.7) 
Eotaxin (CCL11) 4.2 (21.9 - 99.0) 54.8 (17.8 - 103.0) 51.2 (31.5 - 128.7) 
G-CSF 9.9 (9.9 - 33.8) 16.5 (9.9 - 36.4) 28.8 (13.7 - 38.9) 
GM-CSF 15.9 (15.9 - 54.0) 15.9 (15.9 - 15.9) 15.9 (15.9 - 15.9) 
IL-2 36.3 (22.0 - 104.1) 42.4 (22.0 - 106.7) 53.9 (22.0 - 78.8) 
IL-10 2.2 (2.2 - 2.9) 1.8 (0.9 - 3.2) 2.3 (1.3 - 4.4) 
IL-16 799 (412- 1175) 1091 (865 - 1362) 936 (736 - 1386) 
IL-17A 24.3 (24.3 - 358.2) 24.3 (24.3 - 180.3)  24.3 (24.3 - 187.0) 
IL-20 9.1 (7.6 - 50.2) 9.1 (6.1 - 31.7) 8.8 (2.0 - 21.2) 
IL-21 9.1 (9.1 - 9.1) 9.6 (8.9 - 33.8) 13.8 (7.3 - 27. 2) 
IFN-γ 13.1 (6.4 - 13.1) 11.2 (7.3 - 15.5) 18.3 (8.9 - 16.4) 
MDC (CCL22) 46.2 (20.1 - 74.5) 104.6 (51.9 - 164.8) 62.9 (20.0 - 119.3) 
MIP-3α 21.0 (21.0 - 21.0) 24.5 (15.2 - 57.9) 44.8 (16.8 - 96.4) 
TSLP 4.7 (2.4 - 11.6) 4.6 (2.3 - 13.2) 6.4 (4.0 - 8.8) 
TWEAK 409 (216 - 1859) 935 (469 - 1867) 799 (566 - 1566) 
IL-15 9.0 (3.3 - 27.9) 3.3 (3.3 - 3.7) 3.3 (3.3 - 19.4) 
IL-21 9.1 (9.1 - 9.1) 9.6 (8.9 - 33.8) 13.8 (7.3 - 27.2) 
IL-22 17.8 (17.8 - 17.8) 17.8 (17.8 - 34.5) 17.8 (17.8 - 23.6) 
IL-27 17.4 (17.4 - 17.4) 17.4 (17.4 - 22.8) 17.4 (17.4 - 17.4) 
bNGF 0/13 1/14 1/24 
Eotaxin-2 (CCL24) 0/13 2/14 4/24 
FGF-2 0/13 0/14 1/24 
Gro-α (CXCL1) 0/13 0/14 1/24 
IFN-α 1/13 1/14 4/24 
IL-1α 0/13 1/14 2/24 
IL-1β 3/13 3/14 6/24 
IL-3 1/13 5/14 8/24 
IL-4 0/13 0/14 2/24 
IL-5 1/13 1/14 2/24 
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IL-7 0/13 0/14 0/24 
IL-8 1/13 1/14 4/24 
IL-9 0/13 1/14 1/24 
IL-12p70 0/13 1/14 0/24 
IL-13 0/13 1/14 1/24 
IL-23 0/13 0/13 1/24 
IL-31 0/13 1/14 1/24 
LIF 0/13 0/14 1/24 
MCP-3 (CCL7) 0/13 1/14 0/24 
M-CSF 0/13 0/14 0/24 
TNF-α 0/13 0/14 0/24 
TNF-β 0/13 0/14 0/24 
 
Note: Data are expressed as median (interquartile range or IQR). HC, healthy control; Mild, 
patients with mild/moderate COVID-19; Hosp, hospitalized COVID-19 patients. Kruskal-Wallis 
test with Dunn’s corrections was used for comparisons among three groups of HCs, mild/severe 
cases, and hospitalized COVID-19 patients. *p <0.05, **p <0.01, or ***p <0.001 for comparison 
between hospitalized COVID-19 and HCs, #p <0.05 for comparison between hospitalized 
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